NMR-based metabonomic study of Chinese medicine Gegen Qinlian Decoction as an effective treatment for type 2 diabetes in rats

Metabolomics

Volumn 9, Issue 6, 2013, Pages 1228-1242

  Tian, Na ^a   Wang, Junsong ^a   Wang, Pengran ^a   Song, Xingfang ^a   Yang, Minghua ^a   Kong, Lingyi ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

1H NMR spectroscopy; Gegen Qinlian Decoction (GQD); Metabonomics; Plasma; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GEGEN QINLIAN DECOCTION EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG MEGADOSE; FOOD INTAKE; GLUCOSE METABOLISM; HISTOPATHOLOGY; LIPID METABOLISM; MALE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT;

RATTUS;

EID: 84888009471     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-013-0535-8     Document Type: Article

References (61)

1. Beckwith-Hall, B., Nicholson, J., Nicholls, A., Foxall, P., Lindon, J., Connor, S., et al. (1998). Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chemical Research in Toxicology, 11, 260-272.
2. Bino, R. J., Hall, R. D., Fiehn, O., Kopka, J., Saito, K., Draper, J., et al. (2004). Potential of metabolomics as a functional genomics tool. Trends in Plant Science, 9, 418-425.
3. Boden, G., Chen, X., & Stein, T. P. (2001). Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. American Journal of Physiology-Endocrinology and Metabolism, 280, E23-E30.
4. Bond, J. S., Failla, M. L., & Unger, D. F. (1983). Elevated manganese concentration and arginase activity inlivers of streptozotocin-induced diabetic rats. Journal of Biological Chemistry, 258, 8004-8009.
5. Chia, Y. Y., Liong, S. Y., Ton, S. H., & Kadir, K. B. A. (2012). Amelioration of glucose homeostasis by glycyrrhizic acid through gluconeogenesis rate-limiting enzymes. European Journal of Pharmacology, 677, 197-202.
6. Cloarec, O., Dumas, M. E., Craig, A., Barton, R. H., Trygg, J., Hudson, J., et al. (2005). Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Analytical Chemistry, 77, 1282-1289.
7. Dandona, P., Aljada, A., & Bandyopadhyay, A. (2004). Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology, 25, 4-7.
8. Dandona, P., Aljada, A., & Mohanty, P. (2002). The anti-inflammatory and potential anti-atherogenic effect of insulin: A new paradigm. Diabetologia, 45, 924-930.
9. Dennis, J. W., Granovsky, M., & Warren, C. E. (1999). Glycoprotein glycosylation and cancer progression. Biochimica et Biophysica Acta, 1473, 21-34.
10. Dumas, M. E. (2006). Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proceedings of the National Academy of Sciences USA, 103, 12511-12516.
11. 1-acid glycoprotein, ceruloplasmin, haptoglobin and C-reactive protein, in the pig. Veterinary Immunology and Immunopathology, 51, 377-385.
12. El-Deredy, W. (1997). Pattern recognition approaches in biomedical and clinical magnetic resonance spectroscopy: A review. NMR in Biomedicine, 10, 99-124.
13. Fan, T. W. M. (1996). Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures. Progress in Nuclear Magnetic Resonance Spectroscopy, 28, 161-219.
14. Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., et al. (1989). Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. Journal of Clinical Investigation, 84, 205-213.
15. Gu, Y., Zhang, Y. F., Shi, X. Z., Li, X. Y., Hong, J., Chen, J., et al. (2010). Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta, 81, 766-772.
16. Han, S., Mathias, E., & Ba, Y. (2007). Proton NMR determination of Mg2 + and Ca2 + concentrations using tetrasodium EDTA complexes. Journal of Chemistry, 1, 1-5.
17. 1-acid glycoprotein in patients with inflammation and diabetes mellitus. Clinica Chimica Acta, 329, 117-125.
18. Hirosumi, J., Tuncman, G., Chang, L. F., Gorgun, C. Z., Uysal, K. T., Maeda, K., et al. (2002). A central role for JNK in obesity and insulin resistance. Nature, 420, 333-336.
19. Itoh, N., Sakaue, S., Nakagawa, H., Kurogochi, M., Ohira, H., Deguchi, K., et al. (2007). Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism, 293, 1069-1077.
20. 1H NMR spectroscopy and LC/MS method. Chemometrics and Intelligent Laboratory Systems, 97, 11-17.
21. Kong, W. J., Zhang, H., Song, D. Q., Xue, R., Zhao, W., Wei, J., et al. (2009). Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism, Clinical and Experimental, 58, 109-119.
22. Lee, Y. S. (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 55, 2256-2264.
23. Lee, Y. S., Choi, J. W., Hwang, I., Lee, J. W., Lee, J. H., Kim, A. Y., et al. (2010). Adipocytokine orosomucoid integrates inflammatory and metabolic signals to preserve energy homeostasis by resolving immoderate inflammation. Journal of Biological Chemistry, 285, 22174-22185.
24. Li, H., Wang, L., Yan, X. Z., Liu, Q. J., Yu, C. H., Wei, H. D., et al. (2011). A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. Journal of Proteome Research, 10, 2797-2806.
25. Li, W. L., Zheng, H. C., Bukuru, J., & De Kimpe, N. (2004). Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. Journal of Ethnopharmacology, 92, 1-21.
26. Lindon, J. C., Holmes, E., Bollard, M. E., Stanley, E. G., & Nicholson, J. K. (2004). Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers, 9, 1-31.
27. Lindon, J. C., Holmes, E., & Nicholson, J. K. (2001). Pattern recognition methods and applications in biomedical magnetic resonance. Progress in Nuclear Magnetic Resonance Spectroscopy, 39, 1-40.
28. Lindon, J. C., Nicholson, J. K., & Everett, J. R. (1999). NMR Spectroscopy of Biofluids. Annual Reports on NMR Spectroscopy, 38, 1-88.
29. 1H NMR spectroscopy of biological fluids. Analytical Chemistry, 68, 3370-3376.
30. Maher, A. D., Cloarec, O., Patki, P., Craggs, M., Holmes, E., Lindon, J. C., et al. (2009). Dynamic biochemical information recovery in spontaneous human seminal fluid reactions via 1H NMR kinetic statistical total correlation spectroscopy. Analytical Chemistry, 81, 288-295.
31. Markus, W., & Kaddurah-Daouk, R. (2000). Creatine and creatinine metabolism. Physiological Reviews, 80, 1107-1213.
32. 1H NMR metabonomics can differentiate the early atherogenic effect of dairy products in hyperlipidemic hamsters. Atherosclerosis, 1, 127-133.
33. Meezan, E., Meezan, E. M., Jones, K., Moore, R., Barnes, S., & Prasain, J. K. (2005). Contrasting effects of puerarin and daidzin on glucose homeostasis in mice. Journal of Agricultural and Food Chemistry, 53, 8760-8767.
34. Mooradian, A. D. (2009). Dyslipidemia in type 2 diabetes mellitus. Nature Clinical Practice Endocrinology & Metabolism, 5, 150-159.
35. Morris, S. M., Jr. (1992). Regulation of enzymes of urea and arginine synthesis. Annual of Review Nutrition, 12, 81-101.
36. Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002). Metabonomics: A platform for studying drug toxicity and gene function. Nature Reviews Drug Discovery, 1, 153-162.
37. Nicholson, J. K., & Foxall, P. J. D. (1995). 750 MHz 1H and 1H-l3C NMR spectroscopy of human blood plasma. Analytical Chemistry, 67, 793-811.
38. Nicholson, J. K., & Wilson, I. D. (2003). Understanding 'global' systems biology: Metabonomics and the continuum of metabolism. Nature Reviews Drug Discovery, 2, 668-676.
39. 1H-NMR-based metabonom ics. International Journal of Cancer, 113, 782-788.
40. Raubenheimer, P. J. (2006). A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes, 55, 2015-2020.
41. Rossini, A. A., Like, A. A., Chick, W. L., Appel, M. C., & Cahill, G. F. (1977). Studies of streptozotocin-induced insulitis and diabetes. Proceedings of the National Academy of Sciences USA, 74, 2485-2489.
42. Salek, R. M., Maguire, M. L., Bentley, E., Rubtsov, D. V., Hough, T., Cheeseman, M., et al. (2007). A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiological Genomics, 29, 99-108.
43. Sano, T., Umeda, F., Hashimoto, T., Nawata, H., & Utsumi, H. (1998). Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia, 41, 1355-1360.
44. Shockcor, J. P., & Holmes, E. (2005). Metabonomic applications in toxicity screening and disease diagnosis. Integrated Strategies for Drug Discovery Using Mass Spectrometry (pp. 121-147).
45. Sicree, R., Shaw, J., Zimmet, P., & Tapp, R. (2003). The global burden of diabetes. Diabetes Atlas Second Edition (pp. 15-78).
46. Srinivasan, K., & Ramarao, P. (2007). Animal model in type 2 diabetes research: An overview. (2007). Indian Journal of Medical Research, 125, 451-472.
47. Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C. L., & Ramarao, P. (2005). Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacological Research, 52, 313-320.
48. Timbrell, J. A. (1998). Biomarkers in toxicology. Toxicology, 129, 1-12.
49. Tyler Burt, C., & Ribolow, H. (1994). Glycerol phosphorylcholine (GPC) and serine ethanolamine phosphodiester (SEP): Evolutionary mirrored metabolites and their potential metabolic roles. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 108, 11-20.
50. Viant, M. R., Rosenblum, E. S., & Tjeerdema, R. S. (2003). NMR-based metabolomics: A powerful approach for characterizing the effects of environmental stressors on organism health. Environmental Science Technology, 37, 4982-4989.
51. Waisundara, V. Y., Hsu, A., Tan, B. K. H., & Huang, D. (2009). Baicalin improves antioxidant status of streptozotocin-induced diabetic wistar rats. Journal of Agricultural and Food Chemistry, 57, 4096-4102.
52. Waisundara, V. Y., Siu, S. Y., Hsu, A., Huang, D., & Tan, B. K. H. (2011). Baicalin upregulates the genetic expression of antioxidant enzymes in Type-2 diabetic Goto-Kakizaki rats. Life Sciences, 88, 1016-1025.
53. Xiong, F. L., Sun, X. H., Gan, L., Yang, X. L., & Xu, H. B. (2006). Puerarin protects rat pancreatic islets from damage by hydrogen peroxide. European Journal of Pharmacology, 529, 1-7.
54. Yin, J., Xing, H. L., & Ye, J. P. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, Clinical and Experimental, 57, 712-717.
55. Zeng, L. X., Dong, J. C., Yu, W. Q., Huang, J. H., Liu, B. J., & Feng, X. T. (2010). Baicalin attenuates inflammation by inhibiting NF-kB activation in cigarette smoke induced inflammatory models. Pulmonary Pharmacology Therapeutics, 23, 411-419.
56. Zhang, Y. F., Li, X. Y., Zou, D. J., Liu, W., Yang, J. L., Zhu, N., et al. (2008a). Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. Journal of Clinical Endocrinology and Metabolism, 93, 2559-2565.
57. Zhang, W., Liu, C. Q., Wang, P. W., Sun, S. Y., Su, W. J., Zhang, H. J., et al. (2010a). Puerarin improves insulin resistance and modulates adipokine expression in rats fed a high-fat diet. European Journal of Pharmacology, 649, 398-402.
58. 1H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. Analytical Biochemistry, 383, 76-84.
59. Zhang, H., Wei, J., Xue, R., Wu, J. D., Zhao, W., Wang, Z. Z., et al. (2010b). Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, Clinical and Experimental, 59, 285-292.
60. 1H-NMR-based metabonomic analysis of metabolic profiling in diabetic nephropathy rats induced by streptozotocin. American Journal of Physiology-Renal Physiology, 300, F947-F956.
61. Zhou, J. Y., Zhou, S. W., Tang, J. L., Zhang, K. B., Guang, L. X., Huang, Y. P., et al. (2009). Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. European Journal of Pharmacology, 606, 262-268.